{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:50:14Z","timestamp":1782456614919,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00149-y","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:06:27Z","timestamp":1782309987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65\u201375\u00a0years: a real-world study"],"prefix":"10.1007","volume":"61","author":[{"given":"Naryllae","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":false,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-931X","authenticated-orcid":false,"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonggyu","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5763","authenticated-orcid":false,"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"5","key":"149_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"5","key":"149_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/ejh.14165","volume":"112","author":"DH Kim","year":"2024","unstructured":"Kim DH, Youk J, Byun JM, Koh Y, Hong J, Kim TM, et al. Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea. Eur J Haematol. 2024;112(5):743\u201355.","journal-title":"Eur J Haematol"},{"issue":"10","key":"149_CR3","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1007\/s00277-024-05701-3","volume":"103","author":"B Park","year":"2024","unstructured":"Park B, Yoon J, Lee Y, Park Y, Eom H-S. Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study. Ann Hematol. 2024;103(10):4111\u20139.","journal-title":"Ann Hematol"},{"issue":"1","key":"149_CR4","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"149_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"issue":"6","key":"149_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587\u2013600.","journal-title":"J Clin Oncol"},{"issue":"1","key":"149_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12885-025-13615-0","volume":"25","author":"J Yoon","year":"2025","unstructured":"Yoon J, Jung J, Park B, Lee E, Park Y, Yoon S, et al. Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study. BMC Cancer. 2025;25(1):369.","journal-title":"BMC Cancer"},{"issue":"17","key":"149_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"4","key":"149_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202.","journal-title":"Nat Med"},{"issue":"8","key":"149_CR10","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30(8):2235\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"149_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, Harousseau J-L, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44.","journal-title":"Blood Cancer J"},{"issue":"7","key":"149_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ajh.25797","volume":"95","author":"A Belotti","year":"2020","unstructured":"Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, et al. Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65\u201075 years. Am J Hematol. 2020;95(7):759\u201365.","journal-title":"Am J Hematol"},{"issue":"2","key":"149_CR13","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","volume":"12","author":"FB Askeland","year":"2025","unstructured":"Askeland FB, Hauk\u00e5s E, Sl\u00f8rdahl TS, Klostergaard A, Alexandersen T, Osnes L, et al. Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025;12(2):e120\u20137.","journal-title":"Lancet Haematol"},{"issue":"6","key":"149_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115(6):762\u201377.","journal-title":"Int J Hematol"},{"issue":"9","key":"149_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel J, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"1","key":"149_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44313-025-00055-9","volume":"60","author":"SH Jung","year":"2025","unstructured":"Jung SH, Koh Y, Kim MK, Kim JS, Moon JH, Min CK, et al. Correction: evidence\u2011based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions. Blood Res. 2025;60(1):9.","journal-title":"Blood Res"},{"issue":"5","key":"149_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3904\/kjim.2015.408","volume":"31","author":"J Hong","year":"2016","unstructured":"Hong J, Lee JH. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med. 2016;31(5):820.","journal-title":"Korean J Intern Med"},{"issue":"3","key":"149_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","volume":"143","author":"T Facon","year":"2024","unstructured":"Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143(3):224\u201332.","journal-title":"Blood"},{"issue":"2","key":"149_CR19","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1016\/j.jtct.2025.01.672","volume":"31","author":"J Kort","year":"2025","unstructured":"Kort J, Ignatz-Hoover J, Driscoll JJ. Real-world evidence for autologous stem cell transplantation in elderly multiple myeloma patients. Transplant Cell Ther. 2025;31(2):S437\u20138.","journal-title":"Transplant Cell Ther"},{"key":"149_CR20","doi-asserted-by":"publisher","unstructured":"Huang YC, Lim KH, Sung MT, Sun KJ, Chang YC. Outcomes of autologous hematopoietic stem cell transplantation in elderly multiple myeloma patients: a single-center analysis. Int J Gerontol. 2025;19(3):141\u20136. https:\/\/doi.org\/10.6890\/IJGE.202507_19(3).0003.","DOI":"10.6890\/IJGE.202507_19(3).0003"},{"issue":"10","key":"149_CR21","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825\u201337.","journal-title":"Lancet Haematol"},{"issue":"4","key":"149_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"11","key":"149_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"4","key":"149_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066.","journal-title":"Leukemia"},{"issue":"27","key":"149_CR25","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41(27):4416\u201329.","journal-title":"J Clin Oncol"},{"issue":"1","key":"149_CR26","first-page":"286","volume":"111","author":"S Mizuno","year":"2025","unstructured":"Mizuno S, Gras L, Baaij LG, Koster L, D\u2019Souza A, Hari PN, et al. The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. Haematologica. 2025;111(1):286.","journal-title":"Haematologica"},{"issue":"1","key":"149_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-025-13518-0","volume":"25","author":"K-W Kang","year":"2025","unstructured":"Kang K-W, Kim DS, Lee SR, Heo MH, Eom H-S, Jung J, et al. Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma. BMC Cancer. 2025;25(1):204.","journal-title":"BMC Cancer"},{"issue":"3","key":"149_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.20.01370","volume":"39","author":"A Perrot","year":"2021","unstructured":"Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol. 2021;39(3):227\u201337.","journal-title":"J Clin Oncol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00149-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00149-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00149-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:43:32Z","timestamp":1782456212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00149-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00149-y","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}